Subsequent Events	12 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Events On February 15, 2019, the Company and QML entered into a fourth amendment of SOW Two (see Note 16), effective as of February 5, 2019 (such amendment, the “Fourth SOW Two Amendment”). The Fourth SOW Two Amendment contemplates the use of the IUO assay developed in the previous phases of SOW Two in multiple biopharmaceutical company partner clinical trials and additional development activities which potentially could be included in a future companion diagnostic regulatory submission. The development activities to be performed under the Fourth SOW Two Amendment are expected to be completed by the end of 2019. QML has agreed to pay the Company development fees in the low, single-digit millions of dollars for the additional assay development activities. In addition, the Company and QML will share in any net profits (as determined under the Governing Agreement) generated by this development work.

Subsequent Events

12 Months Ended

Dec. 31, 2018

Note 17. Subsequent Events

On February 15, 2019, the Company and QML entered into a fourth amendment of SOW Two (see Note 16), effective as of February 5, 2019 (such amendment, the “Fourth SOW Two Amendment”). The Fourth SOW Two Amendment contemplates the use of the IUO assay developed in the previous phases of SOW Two in multiple biopharmaceutical company partner clinical trials and additional development activities which potentially could be included in a future companion diagnostic regulatory submission.

The development activities to be performed under the Fourth SOW Two Amendment are expected to be completed by the end of 2019. QML has agreed to pay the Company development fees in the low, single-digit millions of dollars for the additional assay development activities. In addition, the Company and QML will share in any net profits (as determined under the Governing Agreement) generated by this development work.